Gastroesophageal Reflux Disease, Transendoscopic Therapies
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage determinations for transendoscopic (transoral/transesophageal) therapies for GERD — including TIF, radiofrequency (Stretta), and endoscopic bulking/prosthetic implantation — for Blue Cross Blue Shield of North Carolina members and providers.
Updated first coverage criteria under Not Covered section to include MUSE and GERDX, now reads: 'Transoral incisionless fundoplication (TIF) (i.e., EsophyX, MUSE, GERDX) is considered investigational as a treatment of gastroesophageal reflux disease.'
Minor edits to the Description section and updates to Policy Guidelines and References in 2024–2026 review cycle.
Coverage Determinations — Transendoscopic Therapies for GERD
Not covered — investigational therapies
Covered when ALL of the following are met
Policy lists specific procedures considered investigational and does not provide approval criteria.
Not Covered / Investigational — transendoscopic and endoscopic therapies considered investigational per policy updates
Transendoscopic and endoscopic therapies are considered investigational (not covered) for GERD in the policy updates noted
Policy history entries document the investigational status and expansions (see 11/8/11, 4/28/15, and 12/10/25 updates).
This policy addresses transendoscopic therapies for gastroesophageal reflux disease (GERD), a group of minimally invasive, endoscopic or transoral/transesophageal procedures developed to reduce reflux by recreating a reflux barrier, applying submucosal thermal lesions, or augmenting the lower esophageal sphincter with injected or implanted materials. Examples cited in the policy include transoral incisionless fundoplication (TIF) devices (EsophyX, MUSE, GERDX), transesophageal radiofrequency ablation (the Stretta procedure), and endoscopic submucosal implantation or injection of bulking agents/prostheses (e.g., polymethylmethacrylate beads, zirconium oxide spheres).
BCBSNC’s stance is that these procedures are considered investigational for the treatment of GERD and therefore are not covered under this medical policy. The policy has been updated over time (including the 12/10/25 revision that explicitly added MUSE and GERDX to the TIF language) and continues to list these techniques under the “When Not Covered”/investigational section.
Transoral incisionless fundoplication (TIF) — specifically devices and systems identified as EsophyX, MUSE, and GERDX — is explicitly designated in this policy as investigational for treatment of GERD and therefore not covered by BCBSNC.
The policy history documents that the TIF language was revised and clarified over multiple updates, most recently amended on 12/10/25 to include MUSE and GERDX alongside EsophyX while maintaining the investigational coverage stance.
The policy explicitly states that transendoscopic/transesophageal therapies for GERD — including TIF, Stretta (transesophageal radiofrequency), and endoscopic bulking/implantation — are considered investigational and therefore not covered by Blue Cross Blue Shield of North Carolina.
Because these procedures are categorized as investigational, claims for these services performed for treatment of GERD are subject to denial under this policy.
Specific procedures enumerated as investigational in the policy include the Stretta procedure (transesophageal radiofrequency to create submucosal thermal lesions of the gastroesophageal junction), transesophageal/transoral incisionless fundoplication approaches (TIF systems such as EsophyX, MUSE, GERDX), and endoscopic submucosal implantation or injection of bulking agents/prostheses (for example, polymethylmethacrylate beads or zirconium oxide spheres).
These items are listed in the “When Not Covered”/exclusions section and are explicitly described as investigational interventions for GERD, consistent with the policy’s long-standing stance and recent clarifications.
Applicable and Historical Procedure Codes
| 0008T | historical code listed in policy history |
| 0133T | historical code listed in policy history |
| S2215 | historical HCPCS code removed |
| 43201 | historical CPT code added/removed in history |
| 43257 | historical CPT code added |
| 43219 | historical CPT code added then removed |
| 43212 | CPT code added to Billing/Coding |
| 43236 | CPT code added to Billing/Coding |
| 43266 | CPT code added to Billing/Coding |
| 43499 | unlisted procedure code included in Billing/Coding updates |
Provider Responsibilities, Billing, and Documentation
Use listed service codes; records may be required
Applicable CPT/HCPCS codes are listed in the policy’s Billing/Coding section; inclusion does not guarantee reimbursement and BCBSNC may request medical records to determine medical necessity. Endoscopic submucosal injection of a bulking agent would most likely be coded using 43201 or 43236; endoscopic implantation of a prosthesis would most likely be coded using 43212, 43266, or 43499.
Follow payer billing/coding and prior authorization
Follow BCBSNC billing/coding and prior authorization processes for endoscopic GERD procedures; the policy’s Billing/Coding section has historically been updated with added and removed codes, so confirm current payer requirements prior to submission.
- Billing/Coding section has been revised historically to add/remove codes (see policy history: multiple entries from 2013–2016 and 2015 additions)
- Providers should follow payer prior authorization and billing guidance as indicated in the full policy
Verify member benefits before applying policy
Verify member benefits and benefit design before applying this medical policy because member coverage may vary by plan and benefit booklet.
- Member benefit language should be reviewed in the Member's Benefit Booklet before applying policy
No step therapy specified in policy
No step therapy requirements are specified in the referenced policy chunks; literature cited compares endoscopic procedures with PPIs or surgical fundoplication rather than step-therapy mandates.
- Scientific background compares TIF/Stretta to medical therapy or surgery; no step therapy rules are listed
- Benefit design still must be checked (see Benefits Application)
Submit complete medical records when requested
BCBSNC may request medical records to determine medical necessity; when records are requested, letters of support or explanation are often useful but are not sufficient unless all specific information needed for the determination is included.
- Medical records may be requested to make a medical necessity determination
- Letters of support/explanation are useful but insufficient unless all required information is provided
Ensure accurate procedure coding
Submit accurate CPT/HCPCS codes that correspond to the performed procedure; the policy history documents additions and removals of codes over time, so ensure coding reflects the actual service provided.
- Policy history shows codes have been added and removed (e.g., 0008T, 0133T, 43219, C9743, etc.)
- Provide the exact CPT/HCPCS code that matches the procedure performed
High denial risk: investigational procedures
Procedures designated investigational in this policy (for example, TIF [EsophyX, MUSE, GERDX], Stretta, and endoscopic bulking/implantation) are not covered; claims for these services may be denied as investigational.
- Policy statement: 'Transendoscopic Therapies for Gastroesophageal Reflux Disease are considered investigational. BCBSNC does not provide coverage for investigational services or procedures.'
- When Not Covered lists TIF (EsophyX, MUSE, GERDX), Stretta, and endoscopic submucosal implantation/injection as investigational
Investigational 'When Not Covered' procedures can be denied
Billing or requesting coverage for procedures identified in the policy’s 'When Not Covered' section (e.g., transoral incisionless fundoplication, Stretta, endoscopic implantation/injection of bulking agents) may trigger denial because these services are classified as investigational and not covered for GERD.
- Specific not-covered examples: TIF (EsophyX, MUSE, GERDX), Stretta, endoscopic submucosal implantation/injection
- Claims for these services may be denied on the basis of investigational status
Clinical Background and Rationale
Transendoscopic therapies are minimally invasive alternatives to medical therapy or surgical fundoplication that aim to reduce gastroesophageal reflux by one of several mechanisms: recreating a gastroesophageal valve (as with TIF), producing submucosal thermal injury at the gastroesophageal junction (as with Stretta) that may alter tissue compliance or nerves, or augmenting the lower esophageal sphincter with injected or implanted bulking agents/prostheses.
Although randomized trials and observational studies are cited in the policy’s background and reference sections, the evidence has not demonstrated consistent, durable objective benefit and safety concerns or loss of effect over time have been reported; for these reasons BCBSNC considers these transendoscopic approaches investigational and does not provide coverage for them.
Procedure and Regulatory Definitions
Policy Changes and Review History
When It Is Not Covered section revised to specify transesophageal endoscopic gastroplasty, transesophageal radiofrequency (Stretta), and endoscopic submucosal implantation/injection of bulking agents as investigational for GERD.
Description section extensively revised and When Not Covered section updated to include transoral incisionless fundoplication; Billing/Coding section revised to add codes 43499 and 43659.
Description, Policy Guidelines, and References updated; Specialty Matched Consultant Advisory Panel and Medical Director reviews documented.
Minor edits to the Description section and References updated following advisory panel and medical director review.
First coverage criterion under Not Covered updated to explicitly list MUSE and GERDX so the Not Covered language reads: 'Transoral incisionless fundoplication (TIF) (i.e., EsophyX, MUSE, GERDX) is considered investigational as a treatment of gastroesophageal reflux disease.'
Policy Guidelines and References updated; Specialty Matched Consultant Advisory Panel and Medical Director reviews through March 2026 documented.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.